These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 19514613)

  • 1. [Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV].
    Urbánek P; Subhanová I; Janousová E; Dusek L; Marecek Z; Brůha R; Petrtýl J; Brodanová M
    Vnitr Lek; 2009 May; 55(5):474-9. PubMed ID: 19514613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C].
    Husa P; Slesinger P; Stroblová H; Svobodník A
    Vnitr Lek; 2006 Feb; 52(2):153-9. PubMed ID: 16623278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia].
    Moon SS; Kang HG; Seo JA; Jung EU; Lee SH; Park SJ; Lee YJ; Seol SY
    Korean J Gastroenterol; 2010 Jul; 56(1):33-8. PubMed ID: 20664316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
    Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
    J Hepatol; 2006 Jan; 44(1):97-103. PubMed ID: 16290907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
    Omori-Mizuno Y; Nakayama N; Inao M; Funyu J; Asabe S; Tomita K; Nishikawa K; Hosoda Y; Tanaka M; Hashimoto Y; Yakabi K; Koshima Y; Mochida S
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1384-90. PubMed ID: 25778685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.
    Antaki N; Hermes A; Hadad M; Ftayeh M; Antaki F; Abdo N; Kebbewar K
    J Viral Hepat; 2008 May; 15(5):383-6. PubMed ID: 18086180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
    Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
    Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin.
    Gazdik F; Gazdikova K; Laktis K; Okruhlica L; Fejdiova K; Danis D; Pijak MR; Wsolova L; Kajaba I; Kratky A
    Bratisl Lek Listy; 2009; 110(2):77-84. PubMed ID: 19408838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.
    Dalgard O; Bjoro K; Ring-Larsen H; Verbaan H
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):552-6. PubMed ID: 20154627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.
    Rumi MG; Aghemo A; Prati GM; D'Ambrosio R; Donato MF; Soffredini R; Del Ninno E; Russo A; Colombo M
    Gastroenterology; 2010 Jan; 138(1):108-15. PubMed ID: 19766645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.